Stockscreener 앱 받기
63.39
0.25%
0.16
시간 외 거래:
63.39
전일 마감가:
$63.23
열려 있는:
$63
하루 거래량:
7.07M
Relative Volume:
1.42
시가총액:
$197.09B
수익:
$51.21B
순이익/손실:
$6.50B
주가수익비율:
32.02
EPS:
1.98
순현금흐름:
$6.76B
1주 성능:
-2.16%
1개월 성능:
-19.00%
6개월 성능:
-17.57%
1년 성능:
-1.15%
1일 변동 폭
$62.75
$63.65
1주일 범위
$62.75
$66.24
52주 변동 폭
$60.47
$87.67
아스트라제네카 ADR Stock (AZN) Company Profile
명칭
Astrazeneca PLC
전화
44 20 3749 5000
주소
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
AZN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| AZN | 63.39 | 197.09B | 51.21B | 6.50B | 6.76B | 1.98 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Sell |
| 2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | 업그레이드 | Argus | Hold → Buy |
| 2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
| 2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-12 | 재개 | JP Morgan | Overweight |
| 2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
| 2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
| 2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2019-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
| 2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-05 | 재확인 | Bernstein | Outperform |
| 2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
AstraZeneca Tries Plan B For Dato-DXd After Regulator Feedback - Citeline
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
AstraZeneca picks first Treg cell therapy from Quell Therapeutics partnership - Pharmaceutical Technology
Is AstraZeneca PLC (AZN) the Best Immunotherapy Stock to Buy Now? - Insider Monkey
Is AstraZeneca PLC (AZN) A Cheap NASDAQ Stock To Invest In Now? - Insider Monkey
AstraZeneca's Tagrisso recommended for EU approval - ShareCast
AstraZeneca: new positive CHMP opinion for Tagrisso - Marketscreener.com
AstraZeneca's cell lung cancer drug sent for EU approval - baha news
Korea’s Lunit in AI-powered lung cancer diagnostics deal with AstraZeneca - Korea Economic Daily
Natixis Advisors LLC Boosts Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca PLC (NASDAQ:AZN) Sees Large Increase in Short Interest - MarketBeat
AstraZeneca PLC (LON:AZN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
AstraZeneca PLC ADR outperforms competitors despite losses on the day - MarketWatch
FIVE at FIVE: GSK, AstraZeneca plummet; LandSec profits; Economy stalls; FTSE 100 meanders; TT snubs Volex - Proactive Investors USA
AstraZeneca PLC (LON:AZN) Insider Pascal Soriot Purchases 20,000 Shares - MarketBeat
Trump anti-vax health appointment wipes £7bn from AstraZeneca and GSK - Proactive Investors USA
FTSE 100 Live: Index regains; GSK, AstraZeneca weighUK economic growth slows - Proactive Investors UK
AstraZeneca rises Thursday, outperforms market - MarketWatch
July 2025 Options Now Available For AstraZeneca (AZN) - Nasdaq
Is AstraZeneca a Buy as It Eyes the Weight Loss Market? - The Motley Fool
AstraZeneca talks up US growth as China problems fester - The Boston Globe
AstraZeneca Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
China has trapped the tiger of AstraZeneca’s growth - Financial Times
AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity (NASDAQ:AZN) - Seeking Alpha
AstraZeneca PLC ADR rises Wednesday, outperforms market - MarketWatch
AstraZeneca pledges $3.5bn to biopharma research and manufacturing - BioProcess Insider
AstraZeneca PLC (NASDAQ:AZN) Q3 2024 Earnings Call Transcript - MSN
AstraZeneca: Stifel confirms its 'buy' rating on the stock - Marketscreener.com
MQS Management LLC Has $832,000 Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Merck and AstraZeneca announce results of Koselugo in neurofibromatosis trial - Yahoo Finance
AstraZeneca plans major $3.5bn expansion drive in the US - Investment Monitor
MSD and AstraZeneca report positive topline data from Koselugo trial for NF1 - Clinical Trials Arena
AstraZeneca PLC (AZN) Q3 2024 Earnings Call Highlights: Strong R - GuruFocus.com
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
AstraZeneca PLC (AZN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
AstraZeneca PLC ADR outperforms competitors on strong trading day - MarketWatch
AstraZeneca Plc (AZN) Q3 2024 Earnings Call Transcript - The Motley Fool
AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US - Yahoo Finance
Trending : AstraZeneca Expands Its Investment Plan in the U.S. - Marketscreener.com
AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously' - AOL
AstraZeneca, Daiichi file for FDA accelerated approval of Dato-DXd (NASDAQ:AZN) - Seeking Alpha
AstraZeneca lifts 2024 outlook, doubles down on US plans - Yahoo Finance UK
AstraZeneca rises Tuesday, outperforms market - MarketWatch
AstraZeneca Talks Up US Growth as China Problems Fester - Bloomberg
AstraZeneca says detained China head has lawyer, but company still in dark - Yahoo Finance UK
AstraZeneca Dodges China Questions While Raising 2024 Outlook With Strong Q3 Sales - BioSpace
ASTRAZENECA : Q3 beat + guidance upgrade weigh lighter than the Chinese uncertainty - Marketscreener.com
Exclusive | AstraZeneca Expands U.S. Investment Plan - The Wall Street Journal
Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial - Marketscreener.com
AstraZeneca to spend $3.5B to expand U.S. operations (NASDAQ:AZN) - Seeking Alpha
AstraZeneca Talks Up US Growth as China Problems Worsen - MSN
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):